A
Andrew James Sanders
Researcher at Cardiff University
Publications - 117
Citations - 3283
Andrew James Sanders is an academic researcher from Cardiff University. The author has contributed to research in topics: Cancer & Cancer cell. The author has an hindex of 26, co-authored 104 publications receiving 2649 citations. Previous affiliations of Andrew James Sanders include Capital Medical University.
Papers
More filters
Journal ArticleDOI
Tissue invasion and metastasis: Molecular, biological and clinical perspectives.
Wen Guo Jiang,Andrew James Sanders,Masaru Katoh,H. Ungefroren,Frank Gieseler,Mark E. Prince,Sarah K. Thompson,Massimo Zollo,Daniela Spano,P. Dhawan,Daniel Sliva,Pochi R. Subbarayan,Malancha Sarkar,Kanya Honoki,Hiromasa Fujii,Alexandros G. Georgakilas,Amedeo Amedei,Elena Niccolai,Amr Amin,S. Salman Ashraf,Lin Ye,William G. Helferich,Xujuan Yang,Chandra S. Boosani,Gunjan Guha,Maria Rosa Ciriolo,Katia Aquilano,Sophie Chen,Asfar S. Azmi,W N Keith,Alan Bilsland,Dipita Bhakta,Dorota Halicka,Somaira Nowsheen,Francesco Pantano,Daniele Santini +35 more
TL;DR: This review lists the disruption of E-cadherin and tight junctions, key signaling pathways, including urokinase type plasminogen activator (uPA), phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene (PI3K/AKT), focal adhesion kinase (FAK), β-catenin/zinc finger E-box binding homeobox 1 (ZEB
Journal ArticleDOI
Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes.
Jason P. Webber,Lisa Kate Spary,Andrew James Sanders,Ruhena Chowdhury,Wen Jiang,Robert Steadman,Jennifer Wymant,Arwyn Tomos Jones,Howard Kynaston,Malcolm David Mason,Zsuzsanna Tabi,Aled Clayton +11 more
TL;DR: Eliminating exosomes from the cancer cell secretome, targeting Rab27a, abolished differentiation and lead to failure in stroma-assisted tumour growth in vivo, and exosomal TGFβ1 is therefore required for the formation of tumour-promoting stroma.
Book Chapter
Cancer invasion and metastasis: molecular and cellular perspective
TL;DR: The role of cell junctions, cell adhesions, epithelial-mesenchymal transition, angio and lymphangiogenesis and organ specific metastasis is discussed.
Journal ArticleDOI
Designing a broad-spectrum integrative approach for cancer prevention and treatment
Keith I. Block,Charlotte Gyllenhaal,Leroy Lowe,Amedeo Amedei,A.R.M. Ruhul Amin,Amr Amin,Katia Aquilano,Jack L. Arbiser,Jack L. Arbiser,Alexandra Arreola,Alla Arzumanyan,S. Salman Ashraf,Asfar S. Azmi,Fabian Benencia,Dipita Bhakta,Alan Bilsland,Anupam Bishayee,Stacy W. Blain,Penny B. Block,Chandra S. Boosani,Thomas E. Carey,Amancio Carnero,Marianeve Carotenuto,Stephanie C. Casey,Mrinmay Chakrabarti,Rupesh Chaturvedi,Georgia Zhuo Chen,Helen Chen,Sophie Chen,Yi Charlie Chen,Beom K. Choi,Maria Rosa Ciriolo,Helen M. Coley,Andrew Collins,Marisa Connell,Sarah Crawford,Colleen S. Curran,Charlotta Dabrosin,Giovanna Damia,Santanu Dasgupta,Ralph J. DeBerardinis,William K. Decker,Punita Dhawan,Anna Mae Diehl,Jin-Tang Dong,Q. Ping Dou,Janice E. Drewa,Eyad Elkord,Bassel F. El-Rayes,Mark A. Feitelson,Dean W. Felsheru,Lynnette R. Ferguson,Carmela Fimognari,Gary L. Firestone,Christian Frezza,Hiromasa Fujii,Mark M. Fuster,Daniele Generali,Alexandros G. Georgakilas,Frank Gieseler,Michael Gilbertson,Michelle F. Green,Brendan Grue,Gunjan Guhal,Dorota Halicka,William G. Helferich,Petr Heneberg,Patricia Hentosh,Matthew D. Hirschey,Lorne J. Hofseth,Randall F. Holcombe,Kanya Honoki,Hsue-Yin Hsu,Gloria S. Huang,Lasse Jensen,Lasse Jensen,Wen Guo Jiang,Lee W. Jones,Phillip Karpowicz,W. Nicol Keith,Sid P. Kerkar,Gazala Khan,Mahin Khatami,Young Hee Ko,Omer Kucuk,Rob J. Kulathinal,Nagi B. Kumar,Byoung S. Kwon,Anne Leb,Michael A. Leab,Ho Young Lee,Terry Lichtor,Liang Tzung Lin,Jason W. Locasale,Balakrishna L. Lokeshwar,Valter D. Longo,Costas A. Lyssiotis,Karen L. MacKenzie,Meenakshi Malhotra,Maria Marino,María L. Martínez-Chantar,Ander Matheu,Christopher Maxwellx,Eoin McDonnell,Alan K. Meeker,Mahya Mehrmohamadi,Kapil Mehta,Gregory A. Michelotti,Ramzi M. Mohammad,Sulma I. Mohammed,D. James Morré,Irfana Muqbil,Vinayak Muralidharcq,Vinayak Muralidharcq,Michael P. Murphy,Ganji Purnachandra Nagaraju,Rita Nahta,Elena Niccolai,Somaira Nowsheen,Carolina Panis,Francesco Pantano,Virginia R. Parslow,Graham Pawelec,Peter L. Pedersen,Brad Poore,Deepak Poudyal,Satya Prakash,Mark E. Prince,Lizzia Raffaghello,Jeffrey C. Rathmell,W. Kimryn Rathmell,Swapan K. Ray,Jörg Reichrath,Sarallah Rezazadeh,Domenico Ribatti,Luigi Ricciardiello,R. Brooks Robeydf,R. Brooks Robeydf,Francis Rodierdh,H.P. Vasantha Rupasinghe,Gian Luigi Russo,Elizabeth P. Ryan,Abbas Samadi,Isidro Sánchez-García,Andrew James Sanders,Daniele Santini,Malancha Sarkar,Tetsuro Sasada,Neeraj K. Saxena,Rodney E. Shackelford,H. M. C. Shantha Kumara,Dipali Sharma,Dong M. Shin,David Sidransky,Markus D. Siegelin,Emanuela Signori,Neetu Singh,Sharanya Sivanand,Daniel Sliva,Carl Smythe,Carmela Spagnuolo,Diana M. Stafforini,John Stagg,Pochi R. Subbarayan,Tabetha Sundin,Wamidh H. Talib,Sarah K. Thompson,Phuoc T. Tran,Hendrik Ungefroren,Matthew G. Vander Heiden,Vasundara Venkateswaran,Dass S. Vinay,Panagiotis J. Vlachostergios,Zongwei Wang,Kathryn E. Wellen,Richard L. Whelan,Eddy S. Yang,Huanjie Yang,Xujuan Yang,Paul Yaswen,Clement G. Yedjou,Xin Yin,Jiyue Zhu,Massimo Zollo +183 more
TL;DR: An international task force of 180 scientists was assembled to explore the concept of a low-toxicity "broad-spectrum" therapeutic approach that could simultaneously target many key pathways and mechanisms, and results suggest that a broad-spectrums approach should be feasible from a safety standpoint.
Journal ArticleDOI
CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer
Chen Xie,Xiaohua Jiang,Xiaohua Jiang,Jingwan Zhang,Ting Ting Sun,J. D. Dong,Andrew James Sanders,R. Y. Diao,R. Y. Diao,Yifei Wang,Kin Lam Fok,Lai Ling Tsang,M. K. Yu,Xiao Hu Zhang,Yiu Wa Chung,Lin Ye,M. Y. Zhao,J. H. Guo,Z. J. Xiao,Hui Y. Lan,Chi-Fai Ng,Kin-Mang Lau,Z. M. Cai,Wen Guo Jiang,Hsiao Chang Chan,Hsiao Chang Chan +25 more
TL;DR: A previously undefined tumor-suppressing role of CFTR is demonstrated and its involvement in regulation of miR-193b in prostate cancer development is demonstrated.